|Delivery||Report Code||Available Format|
|24-72 Working Hours||LS11106|
Stem cells are the cells that have the potential to differentiate into various types of cells in the body. Embryonic stem cells and adult stem cells are the two main types of stem cells. Stem cells could possibly be used to generate cells and tissues for therapy of a variety of diseases including Alzheimer's disease, Parkinson's disease, heart disease, spinal cord injury, diabetes, and arthritis. The global stem cell banking market is expected to grow due to the increasing prevalence of such diseases and increasing awareness among people about the need to preserve stem cells. The umbilical cord blood of the newborn is an abundant source of stem cells. However, some tissues and organs within body, skin, blood, and the lining of intestine are also key source of tissue-specific stem cells. The stem cells are separated from the blood or tissue, processed, tested and preserved in a stem cell bank.
These stored stem cells have application in treating various types of blood disease as well as genetic disorders such as sickle cell anemia, thalassemia, leukemia, and immune disorders. According to the National Cancer Institute, the incidence of leukemia was 13.7 per 100,000 men and women per year between 2010 to 2014 in the U.S. Therefore, the overall demand for stem cell based therapies and stem cell banking is increasing, which is expected to drive the growth of the global stem cell banking market. National Cancer Institute a part of the National Institutes of Health (NIH), is the principal agency for cancer training and research of the U.S. Federal Government.
The global stem cell banking market is segmented based on bank type, service and application. Based on bank type, the global stem cell banking market is segmented into cord blood and cord tissue. Based on service the stem cell banking market is segmented into storage, collection & transportation, processing and analysis the storage services segment is expected to hold the largest share during the forecast period (2017 – 2023).
Stem cell banking has application in the treatment of cerebral palsy, thalassemia, leukemia, diabetes, autism, and others. In particular, the prevalence of diseases such as leukemia is increasing on a tremendous rate, thereby leading to an increase in the demand for stem cell banking. According to Leukemia and Lymphoma Society (LLS), a voluntary health organization engaged in funding research and ensuring access to treatments for blood cancer patients, approximately every 3 minutes one person in the U.S. is diagnosed with a blood cancer. An estimated combined total of 172,910 people in the U.S. are expected to be diagnosed with leukemia, lymphoma or myeloma in 2017, also new cases of leukemia, lymphoma and myeloma are expected to account for 10.2% of the estimated 1,688,780 new cancer cases diagnosed in the U.S., in 2017.
The stem cell market is expected to grow during the forecast period mainly due to the easy extraction methods used and increasing awareness about stem cell therapeutics and their potential in treating various diseases. According to World Health Organization (WHO), cancer is one of the leading causes of morbidity and mortality worldwide, with approximately 14 million new cases in 2012 and the number of new cases are expected to rise by about 70% over the next two decades. With promising results with stem cell therapies in treating such disorders, the increased incidence of these disease is expected to act as a driving factor for the growth of the global stem cell banking market.
The stem cell banking involves high operating cost for the umbilical cord processing and storage. Many people do not opt for stem cell banking due to lack of awareness and high cost of stem cell therapy. Also, frequent changes in legal regulations related to stem cell banking hinder the growth of the global stem cell banking market.
The rising awareness about potential use of cord tissue, collaborations of cord blood banks to gain a larger market share and the with the introduction of various automated procedures being developed in the field of science are expected to provide abundant opportunities to the manufacturers in the global stem cell banking market. In June 2017, Americord started a social media campaign for National Cord Blood Awareness Month to create awareness about various diseases currently being treated with cord blood stem cells.
Insights by Geography
North America holds the largest share in the global stem cell banking market since the majority of stem cell banking players are based in the region. The growth in the North American stem cell banking industry is mainly due to the increase in awareness among people regarding stem cell banks.
The Asia-Pacific stem cell banking market is expected to grow at the fastest rate during the forecast period due to the increasing investment by government and development of new technologies, which leads to the growth in the emerging countries such as China, Japan and India.
Many players in the global stem cell banking market are collaborating to expand their presence in new geographies and also to get access to the proprietary technologies of other companies.
In June 2017, LifeCodexx AG, a provider of non-invasive prenatal DNA testing in the Europe, announced its partnership with LifeCell International Pvt. Ltd., an Indian mother & baby preventive health care provider, to bring PrenaTesT, qNIPT testing for the first time to India. The qNIPT technology that detects the presence of foetal trisomy 21 (Down Syndrome) from maternal blood, received CE marking (European Conformity) in December 2016.
In July 2014, Cordlife Group Limited and China Cord Blood Corporation announced that the two companies collaborated in order to assist patients across the China, Singapore, Hong Kong, Indonesia, India, the Philippines and Malaysia to identify suitable cord blood matching units for stem cell therapy.
Some of the major players operating in the stem cell banking market include Cordlife Group Ltd, Cryocell International, Inc., Lifecell International Pvt. Ltd., PerkinElmer, Inc. (Viacord), StemCyte Inc., CryoSave AG, China Cord Blood Corporation, Cord Blood America, Inc., Caladrius Biosciences Inc., CBR Systems, Inc., Cordvida, Cordviva India.
By Bank Type